invivodata Announces Improved SitePRO Solution for Site-Based ePRO Assessments
invivodata offers large-screen SitePRO solution to deliver reliability and cost savings.
Pittsburgh, PA— May 19, 2008—invivodata inc. (www.invivodata.com), the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced the launch of its improved SitePRO® solution for in-clinic PRO assessments. The SitePRO Tablet, invivodata’s second-generation large-screen solution, meets sponsor goals to automate paper-based site assessments and enables clinical trial sponsors to manage both site- and patient-based assessment data in a single source.
The SitePRO Tablet utilizes the same, proven invivodata SitePRO software used successfully in dozens of site-based ePRO studies and is the industry’s only site-based ePRO solution to have collected primary efficacy data in support of a successful New Drug Application (NDA). It runs on a Microsoft Windows device that contains a full-sized, 12-inch display screen and offers significant advantages over other currently available site-based ePRO solutions, including these:
- Accurately captures lengthy quality-of-life and other in-clinic-based assessments in either portrait or landscape mode.
- Allows for more accurate transition from paper to electronic assessments and handles large scales without compromise.
- The migration of a paper scale to a SitePRO Tablet in many cases will not require a modification to the core assessment layout, reducing or eliminating validation costs.
“We are pleased to offer this larger screen solution to meet our customers’ in-clinic PRO assessment needs,” said Tom Henson, invivodata vice president of marketing. “And we are confident that the SitePRO Tablet’s multiple data transfer options will provide the flexibility that investigative site personnel require, making it easy for them to capture and transfer PRO data during clinical trials.”
invivodata will demonstrate the SitePRO Tablet, which is now available for clinical trials, at the Drug Information Association (DIA) Annual Meeting in Boston, June 22–25, 2008 in Booth 600.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
